What's new?
27/09/2017

Paris, France – September 27th, 2017 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Henrijette Richter as Managing Partner. She joins Antoine Papiernik, Denis Lucquin, Graziano Seghezzi and Monique Saulnier in the company’s Managing Partnership. With a 14 years’ experience in venture capital, Henrijette brings her extensive industry experience and strong international network to Sofinnova Partners’ leadership.

Henrijette joined Sofinnova Partners in October 2014, after seven years at Novo Holdings A/S (the holding company in the Novo Group) where she co-founded Novo Seeds. Prior to that, she worked at Sunstone Capital and was part of the founding team when the fund spun out of The Danish Growth Foundation. Henrijette is a scientist by training, she holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen, and did her postdoctoral fellowship at MIT Center for Cancer Research, Cambridge, MA.

Since 2014, Henrijette has lead key investments such as in Asceneuron, a biotech company specialized in neurodegenerative diseases headquartered in Switzerland where she also serves on the Board of Directors. Henrijette also seeded and invested in Delinia, a US-based company specialized in the treatment of auto-immune disorders that was sold to Celgene Corporation in January 2017 for a total value of up to $775 M.

Henrijette Richter says: « I am honored by this new role and excited to take a more active role in Sofinnova Partners’ growth strategy to reinforce its global leadership in Life Sciences. I have the foremost respect for the team, its values, the culture of diversity, and the entrepreneur-oriented spirit it has been fostering worldwide for more than forty years ».

Antoine Papiernik, Chairman of Sofinnova Partners, adds: « Henrijette stands out for her investment track record and has demonstrated impressive team leading skills. She is a great addition to our team, and we are extremely pleased to welcome her to the Managing Partnership as Sofinnova Partners is entering a new phase of its development ».
Press contact for SOFINNOVA PARTNERS
Anne REIN
Tel: +33 6 03 35 92 05
@: anne.rein@strategiesimage.com

08/05/2000
29/03/2000
23/03/2000
15/02/2000
14/02/2000
27/01/2000
04/11/1999

Hayward CA. -Kosan Biosciences, Inc. announced today that Susan M. Kanaya has joined the company as Vice President, Finance and Chief Financial Officer.


“Susan brings more than fifteen years of experience in financial planning and management to Kosan,” said Michael S. Ostrach, Chief Operating Officer. “Her expertise will be extremely valuable as Kosan continues its development from a development stage company into an operating company.”


Prior to joining Kosan, Ms. Kanaya was Vice President, Finance at SUGEN, Inc., a publicly-held biotechnology company that recently became a subsidiary of Pharmacia & Upjohn. Since joining SUGEN in 1994 Ms. Kanaya held various positions in Finance and was responsible for financial planning and analysis, financial reporting, corporate financings and treasury and risk management.


Before joining SUGEN, Ms. Kanaya was the Controller at 50/50 Micro Electronics, Inc. and at Power Up Software Corporation. She also held financial analyst and accounting positions at American President Lines, Ltd., Wells Fargo Bank and KPMG Peat Marwick.


Ms. Kanaya graduated from the University of California, Berkeley with a BS in Business Administration, with an emphasis on Accounting and Finance.


Kosan Biosciences, Inc. is a privately held biotechnology company focused on generating small molecule compounds by genetic engineering of biosynthetic pathways, with an initial focus on polyketides. Kosan’s technology permits modifications of polyketides not feasible by chemical methods, greatly expanding the repertoire of polyketides. Therapeutic targets for the Company’s compounds include infectious diseases, gastrointestinal motility disorders, respiratory inflammation, cancer, nerve regeneration and immunosuppression.


For further information :


Daniel V. Santi, M.D., Ph.D. CEO and President KOSAN Biosciences, Inc. 3832 Bay Center Pl. Hayward, CA 94545 www.kosan.com Tel: 510-732-8400 ext. 204 Fax: 510-732-8401


Andrew Lloyd & Associates 95 Ditchling Road Brighton BN1 4ST +44-1273 675100 – Andrew Lloyd email : allo@ala.com


Visit website http://www.kosan.com

29/10/1999

Allschwil. Actelion Ltd. today announced that it has begun its international
Phase III clinical development program on tezosentan for intravenous use in
patients with acute heart failure.


Tezosentan is the first endothelin receptor antagonist optimized for the
treatment of acute pathological conditions. It has a rapid onset of action and a
short half-life allowing an easy titration. The results of the US Phase II
clinical trials will be presented at the American Heart Association Meeting in
Atlanta early November.


“Our goal is to establish tezosentan as the major emergency drug for the
treatment of acute heart failure,” commented Martine Clozel, Vice-President at
Actelion and discoverer of tezosentan. “We believe that tezosentan may have
substantial benefits over existing therapy.”


Acute heart failure is a clinical entity resulting from an acute failure of
the cardiac pump to meet the needs of peripheral metabolism. It is the number
one cause of hospitalization in the elderly. In the US alone, more than 1.5
million patients are hospitalized per year for acute heart failure.


Located in Allschwil, Switzerland, Actelion Ltd. is an emerging
pharmaceutical company aiming to bring to the market innovative proprietary
drugs through creative science related to the endothelium. Founded in December
1997, Actelion Ltd. is backed by leading international venture capital and
private investment funds.

Contact person for Actelion: Dr. Peter
Herrmann, Vice President, Head of Drug Registration and Communication Phone: +41
61 487 45 39, E-mail peter.herrmann@actelion.com


Visit website http://www.actelion.com